Latest Insider Transactions at Dexcom Inc (DXCM)
This section provides a real-time view of insider transactions for Dexcom Inc (DXCM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of DEXCOM INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of DEXCOM INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 18
2021
|
Nicholas Augustinos Director |
BUY
Other acquisition or disposition
|
Direct |
2,192
+42.24%
|
-
|
|
Mar 11
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
1,867
-10.37%
|
$662,785
$355.86 P/Share
|
|
Mar 10
2021
|
Donald Abbey EVP Global Business Services I |
SELL
Open market or private sale
|
Direct |
5,566
-10.03%
|
$2,014,892
$362.92 P/Share
|
|
Mar 10
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Open market or private sale
|
Direct |
5,566
-13.62%
|
$2,014,892
$362.92 P/Share
|
|
Mar 10
2021
|
Quentin S. Blackford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,509
-12.6%
|
$2,356,258
$362.22 P/Share
|
|
Mar 10
2021
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,353
-4.83%
|
$1,937,786
$362.92 P/Share
|
|
Mar 10
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,471
-14.64%
|
$1,256,502
$362.92 P/Share
|
|
Mar 10
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
5,566
-9.11%
|
$2,014,892
$362.92 P/Share
|
|
Mar 10
2021
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
14,044
-10.68%
|
$5,083,928
$362.92 P/Share
|
|
Mar 10
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
2,700
-13.04%
|
$977,400
$362.92 P/Share
|
|
Mar 10
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
941
-5.86%
|
$340,642
$362.92 P/Share
|
|
Mar 09
2021
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
3,857
-0.41%
|
$1,388,520
$360.86 P/Share
|
|
Mar 09
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
152
-0.73%
|
$54,112
$356.94 P/Share
|
|
Mar 08
2021
|
Donald Abbey EVP Global Business Services I |
BUY
Grant, award, or other acquisition
|
Direct |
5,301
+8.72%
|
-
|
|
Mar 08
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
BUY
Grant, award, or other acquisition
|
Direct |
5,301
+11.48%
|
-
|
|
Mar 08
2021
|
Quentin S. Blackford Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,491
+12.66%
|
-
|
|
Mar 08
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,634
+19.2%
|
-
|
|
Mar 08
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
BUY
Grant, award, or other acquisition
|
Direct |
5,301
+7.98%
|
-
|
|
Mar 08
2021
|
Barry J. Regan EVP Operations |
BUY
Grant, award, or other acquisition
|
Direct |
5,301
+28.18%
|
-
|
|
Mar 08
2021
|
Kevin R Sayer Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
13,445
+9.03%
|
-
|
|
Mar 08
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,073
+12.84%
|
-
|
|
Mar 08
2021
|
Sadie Stern EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,634
+28.93%
|
-
|
|
Mar 08
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,301
+24.83%
|
-
|
|
Mar 08
2021
|
Jacob Steven Leach EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,171
+6.08%
|
-
|
|
Feb 26
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.69%
|
$198,000
$396.79 P/Share
|
|
Feb 24
2021
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Open market or private sale
|
Indirect |
1,110
-12.51%
|
$448,440
$404.0 P/Share
|
|
Feb 24
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
600
-5.31%
|
$242,400
$404.0 P/Share
|
|
Feb 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-1.9%
|
$438,074
$406.98 P/Share
|
|
Feb 19
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,800
-3.07%
|
$756,000
$420.01 P/Share
|
|
Feb 17
2021
|
Kevin R Sayer Chairman, CEO & President |
SELL
Bona fide gift
|
Direct |
10,000
-7.58%
|
-
|
|
Feb 16
2021
|
Nicholas Augustinos Director |
SELL
Open market or private sale
|
Indirect |
1,875
-15.67%
|
$772,500
$412.03 P/Share
|
|
Feb 01
2021
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
12,468
-1.28%
|
$4,687,968
$376.93 P/Share
|
|
Jan 27
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.62%
|
$179,500
$359.7 P/Share
|
|
Jan 22
2021
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Open market or private sale
|
Indirect |
1,110
-2.32%
|
$409,590
$369.45 P/Share
|
|
Jan 22
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-0.45%
|
$398,151
$369.77 P/Share
|
|
Jan 13
2021
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
7,073
-0.68%
|
$2,510,915
$355.05 P/Share
|
|
Jan 12
2021
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
39,949
-10.46%
|
$14,381,640
$360.9 P/Share
|
|
Jan 08
2021
|
Kevin R Sayer Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
75,910
+28.4%
|
-
|
|
Jan 06
2021
|
Nicholas Augustinos Director |
SELL
Open market or private sale
|
Indirect |
625
-4.96%
|
$234,375
$375.0 P/Share
|
|
Jan 04
2021
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
11,025
-11.31%
|
$4,013,100
$364.73 P/Share
|
|
Dec 29
2020
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Bona fide gift
|
Direct |
950
-2.84%
|
-
|
|
Dec 28
2020
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.55%
|
$177,500
$355.39 P/Share
|
|
Dec 23
2020
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Open market or private sale
|
Indirect |
1,110
-1.49%
|
$399,600
$360.59 P/Share
|
|
Dec 23
2020
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-0.26%
|
$389,519
$361.24 P/Share
|
|
Dec 16
2020
|
Nicholas Augustinos Director |
SELL
Open market or private sale
|
Indirect |
1,250
-3.08%
|
$442,500
$354.34 P/Share
|
|
Dec 15
2020
|
Bridgette P Heller Director |
SELL
Open market or private sale
|
Direct |
375
-9.81%
|
$133,500
$356.65 P/Share
|
|
Dec 01
2020
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
6,154
-23.92%
|
$2,000,050
$325.0 P/Share
|
|
Dec 01
2020
|
Kevin R Sayer Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
13,233
-2.14%
|
$4,261,026
$322.2 P/Share
|
|
Nov 24
2020
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
600
-5.04%
|
$192,000
$320.37 P/Share
|
|
Nov 23
2020
|
Richard Doubleday EVP Chief Commercial Officer |
SELL
Open market or private sale
|
Indirect |
1,110
-9.1%
|
$352,980
$318.99 P/Share
|